The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
about
Annexin II regulates fibrin homeostasis and neoangiogenesis in vivoMouse aortic ring assay: A new approach of the molecular genetics of angiogenesisAnimal models and the tumor microenvironment: studies of tumor-host symbiosisStructural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineMaspin inhibits cell migration in the absence of protease inhibitory activityThe solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migrationTransient reduction of placental angiogenesis in PAI-1-deficient miceShear stress-induced Ets-1 modulates protease inhibitor expression in microvascular endothelial cellsInvolvement of urokinase-type plasminogen activator in sphingosylphosphorylcholine-induced angiogenesisPAI-1-dependent endothelial cell death determines severity of radiation-induced intestinal injuryA new method for in vivo visualization of vessel remodeling using a near-infrared dye.Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration.Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.Does plasminogen activator inhibitor-1 drive lymphangiogenesis?Testosterone suppresses protective responses of the liver to blood-stage malaria.Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycleCancer and the tumor microenvironment: a review of an essential relationship.Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.Plasminogen activator inhibitor-1 and the kidney.Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.Pleiotropic functions of plasminogen activator inhibitor-1.Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancer.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerTissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis.The ternary complex factor Net regulates cell migration through inhibition of PAI-1 expressionDiet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient miceAdipose-derived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potentialPlasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancerAngiogenesis modulates adipogenesis and obesity.Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.Plasminogen activator inhibitor-1 deficient mice are protected from angiotensin II-induced fibrosisProteases, extracellular matrix, and cancer: a workshop of the path B study sectionMolecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.Blood-brain barrier modeling with co-cultured neural progenitor cell-derived astrocytes and neurons.Membrane associated proteases and their inhibitors in tumour angiogenesis.Manipulating angiogenesis in medicine.Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1.
P2860
Q24623508-A1D223E3-5774-4D0F-A57D-B9AD37180D5AQ24797401-3F442705-BF19-46FD-832A-E6E0F494FC62Q26853538-053553BF-5886-4BFE-B3EF-3894D8409472Q27666429-4FBD8AF8-B69C-4139-9048-476C5AFFFBB6Q28067626-880D920C-F238-4CC2-A803-00760241E597Q28207990-796CC9D5-605C-4CFF-BA40-AFFD7A2D35A7Q28259956-99523EBC-3155-4D1A-8473-0D14AB3EFE94Q28510418-8F673FB9-F1A7-45C0-9A3E-349227A7B1C6Q28565567-82C15187-C4F2-4E72-83EA-C2E4DEF898F1Q28582277-BFD40061-5ADF-4794-B95D-D06FF23806EBQ28730314-DA635199-D712-48BC-A6E5-48E58853D738Q30427664-98BCDB07-9339-4B10-A518-27DEC0CA48F6Q30499994-E0EAE60B-3811-46C8-9F1E-02810C43F613Q33295022-5ACA7003-5BE7-422E-BBDC-27A0A649C791Q33543002-8CBC1CC1-0DEC-48C5-ABF1-1A1CB91E8061Q33558743-697127AB-7A1A-416E-9CDE-DFA49F387B00Q33715393-6D63A5B5-4740-4B1A-A9C6-75EA7B9613DEQ33806357-EDEF4434-A5D9-4053-88AA-589D586842F0Q33812093-6B7E6851-5281-4248-9B9F-250CA5A98057Q33960082-FC416DD9-0627-4EED-A1DA-A283CBA61F67Q33962566-5C9B5B21-94B4-4BA9-A864-3D874656122DQ33984228-AD8DB890-55D5-4BA5-8B12-F15A2D0D1BCEQ34077651-A576145C-F6DF-414D-95F0-870948D14D3CQ34128953-F8C6DEBA-CD57-4309-B7D5-38FB9559A68AQ34202920-98DCE799-D115-436B-8405-EDCC5D0336B2Q34230893-7EC0FFBF-694B-4805-BB71-52302E3F091DQ34346225-10F18FBA-0942-4923-B4A5-C3989FFC2676Q34393020-D75D8BCF-FF33-4F62-815D-7B7555CEDBF1Q34393297-0EE8DE97-6EA2-40F8-8E4B-6F9BADD98283Q34677131-E71E5FF7-5A27-4883-987F-03CE5F804F33Q34725029-5BF84616-62F2-4C34-9004-7CBDBE4C2D83Q34735474-B7B2AED7-E84D-441B-AA62-E5D19BEFDF85Q34887726-BE5E743F-0772-47D6-8CA1-3794E3734386Q34984527-6F5A8507-4B20-4C53-913F-1D2037CDDC92Q35097428-A5C4D26B-487B-4E2B-ADC7-0ED191710DD7Q35219000-9A1139C0-AD92-441E-A27E-7D7BA4A3A000Q35341255-E635AE72-DEA5-49AD-9309-572220B4E5EAQ35587684-043C4EB3-CD8B-412B-88A2-E02B1867B6ADQ35743851-DD4CB34E-9A04-4772-8C67-652C18420F7DQ35791725-35C0F88F-77D3-417A-BA41-ABA708AA3FB7
P2860
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
description
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Februar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2002/02/01)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/02/01)
@nl
наукова стаття, опублікована в лютому 2002
@uk
مقالة علمية (نشرت في فبراير 2002)
@ar
name
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@ast
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@en
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@nl
type
label
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@ast
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@en
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@nl
prefLabel
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@ast
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@en
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@nl
P2093
P50
P3181
P356
P1433
P1476
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
@en
P2093
Christine Grignet-Debrus
Geert Carmeliet
Jean-Michel Foidart
Laetitia Devy
Peter Carmeliet
Robert D Gerard
Silvia Blacher
Veronique Masson
P304
P3181
P356
10.1096/FJ.01-0552COM
P407
P577
2002-02-01T00:00:00Z